読み込み中
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
終値時点
$10.29
$0.00 · 0.00%
時間外
$10.29
$0.00 · 0.00%
10月12日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日中レンジ
現在 $10.29
52週レンジ
現在 $10.29
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
88
大幅な割安
センチメント
72
強気
リスク
39
中程度のリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日中レンジ
現在 $10.29
52週レンジ
現在 $10.29
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.28億 USD | 2.3億 USD | 2.36億 USD | 2.28億 USD | 2.53億 USD |
| 売上原価 | 5815.7万 USD | 6440.4万 USD | 6268.2万 USD | 5509.3万 USD | 6370.1万 USD |
| 粗利益 | 1.7億 USD | 1.66億 USD | 1.73億 USD | 1.73億 USD | 1.89億 USD |
| 研究開発 | 6206.8万 USD | 5493.5万 USD | 5038.2万 USD | 5224万 USD | 7187万 USD |
| 販売・一般管理 | 7120.9万 USD | 8016.3万 USD | 8930.8万 USD | 8997.8万 USD | 1.16億 USD |
| 営業費用 | 1.33億 USD | 1.35億 USD | 1.4億 USD | 1.49億 USD | 1.88億 USD |
| 受取利息 | 407.8万 USD | 472.4万 USD | 260.5万 USD | 81.3万 USD | 16万 USD |
| 支払利息 | 662.2万 USD | 1245.2万 USD | 1333万 USD | 1159.2万 USD | 1280.7万 USD |
| 減価償却費と償却費 | 1093.8万 USD | 1152.4万 USD | 1151.9万 USD | 984万 USD | 1130.5万 USD |
| 営業利益 | 3729.9万 USD | 3096.6万 USD | 3264万 USD | 2372万 USD | 129万 USD |
| 純利益 | 3111.1万 USD | 3027.8万 USD | 2159.1万 USD | 2000 USD | −2912.6万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Avantis U.S. Small Cap Value ETFAVUV2484.54万0.08%308.51億 USD0.25%$119.94+0.25%
iShares Russell 2000 ETFIWM1225.73万0.02%787.4億 USD0.19%$277.88-0.38%
Vanguard Morningstar Total Stock Market ETFVTI1223.58万0.00%2.3兆 USD0.03%$381.57-0.10%
Vanguard Extended Market ETFVXF418.73万0.00%954億 USD0.05%$233.52-0.63%
Dimensional - US Targeted Value ETFDFAT397.73万0.01%301.22億 USD0.33%$67.42+0.22%
Dimensional - US Small Cap ETFDFAS390.07万0.01%338.69億 USD0.31%$78.17-0.23%
EA Bridgeway Omni Small-Cap Value ETFBSVO254万0.11%23.91億 USD0.45%$28.50+0.46%
Vanguard Russell 2000 ETFVTWO231.8万0.01%180億 USD0.06%$112.27-0.35%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATDimensional - US Small Cap ETFDFASEA Bridgeway Omni Small-Cap Value ETFBSVOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
